Skip to main content

Table 1 AML patients’ characteristics

From: Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma

AML sample Gender Age (yo) WHO 2008 category Karyotype NPM1,FLT3-ITD, CEBPA and DNMT3A mutational status Chemosensitivity
#1 M 28 AML NOS, without maturation 46, XY FLT3 ITD CS
#2 M 40 AML with mutated CEBPA 46, XY CEBPAmut  
#3 F 34 AML with myelodysplasia-related changes 45, XX, −7 FLT3 ITDneg, NPM1wt CR
#4 M 45 AML with t(6,9)(p23;q34);DEK-NUP214 46, XY, t(6;9)(p23;q34) FLT3 ITD CS
#6 M 61 AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 45, X–Y, t(8;21)(q22;q22)[19]/46, XY FLT3 ITDneg, NPM1wt CS
#7 F 58 AML with myelodysplasia-related changes 46, XX, del(5)(q23q33), t(8;9)(p11;q34) FLT3 ITDneg, NPM1wt  
#8 M 24 AML with myelodysplasia-related changes 46, XY FLT3 ITDneg, NPM1wt  
#9 M 49 AML with myelodysplasia-related changes Complex karyotype FLT3 ITDneg, NPM1wt  
#10 F 66 AML with myelodysplasia-related changes 46, XX, del(11)(q22q23) FLT3 ITD  
#11 M 22 AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 45, X, −Y, t(8;21)(q22;q22)/46, XY FLT3 ITD CS
#12 F 22 AML with inv(16)(p13.1q22);CBFB-MYH11 46, XX, inv(16)(p13q22)/46, XX FLT3 ITDneg, NPM1wt  
#13 M 37 AML with mutated NPM1 46, XY NPM1mut, DNMT3Amut  
#14 M 42 AML with mutated NPM1 46, XY NPM1mut, FLT3 ITD  
#15 F 60 AML with myelodysplasia-related changes 48, XX, +8, +21 FLT3 ITDneg, NPM1wt  
#16 F 62 AML NOS, with maturation 46, XX FLT3 ITDneg, NPM1wt  
#17 F 60 AML with myelodysplasia-related changes Complex karyotype FLT3 ITDneg, NPM1wt  
#18 F 55 AML with inv(16)(p13.1q22);CBFB-MYH11 46, XX, inv(16)(p13q22)/46, XX FLT3 ITDneg, NPM1wt  
#19 M 63 AML with myelodysplasia-related changes 46, XY FLT3 ITD CR
#20 M 61 AML with mutated NPM1 46, XY NPM1mut, DNMT3Amut CR
#21 F 51 AML NOS, acute monoblastic leukemia Not available NPM1mut, FLT3 ITDneg  
#22 F 36 AML with mutated NPM1 46, XX NPM1mut, FLT3 ITDneg  
  1. M male, F female, yo years old, FLT3-ITD FLT3 internal tandem duplication, CEBPA mut biallelic CEBPA mutation, FLT3 ITD neg absence of FLT3-ITD, NPM1wt wild-type NPM1, NPM1 mut mutated NPM1, Wt wildtype
\